Platelet-Rich Products and Their Application to Osteoarthritis.
Authors: Garbin Livia Camargo, Olver Christine S
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Platelet-Rich Products and Osteoarthritis Osteoarthritis remains one of the most significant causes of chronic musculoskeletal disability in horses, yet effective disease-modifying treatments are lacking. Garbin and Olver conducted a comprehensive review of autologous platelet-rich plasma (PRP) as a therapeutic intervention for OA, examining how growth factors and cytokines released from platelet degranulation might modulate inflammation and support tissue healing. Whilst PRP offers practical advantages over more complex biological therapies such as stem cell treatment and is theoretically capable of promoting functional matrix production, the authors identified substantial inconsistencies in clinical outcomes attributable to variable preparation methods, divergent application protocols, and individual variability between horses. These methodological inconsistencies currently prevent reliable conclusions about efficacy for routine clinical use. For equine professionals considering PRP as part of OA management, this review underscores the importance of standardising production and delivery methods; practitioners should recognise that PRP's current evidence base, whilst promising, remains heterogeneous and warrants careful case selection until more rigorous clinical protocols are established.
Read the full abstract on PubMed
Practical Takeaways
- •PRP offers a more accessible alternative to stem cell therapy for managing osteoarthritis in horses, though standardization of preparation methods is needed
- •Inconsistency in PRP production and application means clinical outcomes may vary; practitioners should be aware that evidence quality is still limited despite theoretical benefits
- •Before investing in PRP treatments, verify the preparation protocol being used, as different methods produce substantially different products with potentially different efficacy
Key Findings
- •PRP is a more practical and accessible biological treatment option for equine osteoarthritis compared to stem cell therapies
- •PRP works by releasing growth factors and cytokines that modulate inflammation and support healing processes
- •Significant variability in PRP preparation methods and application protocols limits reliable conclusions about clinical efficacy
- •No effective disease-modifying treatment currently exists for equine osteoarthritis, making inflammation-modulating therapies like PRP potentially valuable